Document is current
Any future updates will be listed below
-
Authors
Kim, Daniel Y.
Pavlis, Michelle
Huhmann, Linden
Hwang, Jonathan C.
Brophy, Mary T.
Do, Nhan V.
Fillmore, Nathanael
Hartman, Rebecca I.
- License Information
-
More Information
Article History
Received: 13 April 2025
Revised: 29 July 2025
Accepted: 3 September 2025
First Online: 15 September 2025
Declarations
:
: Mr. Kim is a paid consultant for Verve Therapeutics and SeQure Dx, unrelated to this research. Dr. Hartman is a scientific officer for Evereden, unrelated to this research. Dr. Hartman is a consultant and has received honoraria from Oasis Pharmaceuticals, Almirall, Med Learning Group, and MJH Life Sciences, outside the scope of the submitted work. The interests of Mr. Kim and Dr. Hartman have been reviewed and are managed by the Veterans Health Administration and Mass General Brigham in accordance with their conflict-of-interest policies.
: Not applicable.
: Approved by the VA Boston Healthcare System (Protocol #3209).
: The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.
